Michelle Griffin
Director/Board Member at ADAPTIVE BIOTECHNOLOGIES CORPORATION
Net worth: 18 785 $ as of 2024-03-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
John Lubniewski | M | 60 | 13 years | |
Shaun McMeans | M | 62 | 12 years | |
Chad Robins | M | 49 | 15 years | |
Robert Hershberg | M | 61 |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | 17 years |
Kathleen McKereghan Deeley | F | - |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA.
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | 17 years |
R. Clifton | M | 51 | 1 years | |
Ann Hanham | M | 71 | 8 years | |
Laura L. Godlewski | F | 45 | 9 years | |
Tanya Hayden | F | 44 | 3 years | |
Katey Owen | M | 55 | 3 years | |
Bernie Paul | M | 65 |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | 11 years |
Kyle Piskel | M | 40 | 3 years | |
Stacy Taylor | F | 64 | 5 years | |
Noopur Liffick | F | - | 4 years | |
Julie Rubinstein | F | 52 | 13 years | |
Jason Kneeland | M | - | 7 years | |
Harlan Robins | M | 51 | 15 years | |
Mary Pat Lancelotta | F | - | - | |
Lee Roy McCracken | M | 66 | 9 years | |
Donald Joseph | M | 70 | 6 years | |
Peter Neupert | M | 68 | 10 years | |
Jefferson E. Davis | M | 57 | 9 years | |
Michael Pellini | M | 58 | 6 years | |
Francis Lo | M | 43 | 5 years | |
Sharon Benzeno | M | 50 | 10 years | |
Karina Calzadilla | F | - | - | |
Christopher Kiritsy | M | 59 | 2 years | |
Renee Carroll | F | - | 4 years | |
Thomas Dubensky | M | 66 | 2 years | |
Kim Tharaldsen | F | - | 6 years | |
Patrick Mallon | M | - |
Polynoma LLC
Polynoma LLC BiotechnologyHealth Technology Part of CK Life Sciences International (Holdings), Inc., Polynoma LLC is an immuno-oncology focused biopharmaceutical company headquartered in San Diego, CA. Polynoma's lead asset is a novel polyvalent antigen vaccine, Seviprotimut-L, for the prevention of recurrence of melanoma. The vaccine has been safely administered in more than 1,000 patients. Polynoma is an immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. The private company was founded by Paul A. Hopper. | 12 years |
Joshua Schafer | M | 53 | 1 years | |
Jason Michael Ball | M | - | 3 years | |
Zhou Yi | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michelle Burris | F | 58 |
Polynoma LLC
Polynoma LLC BiotechnologyHealth Technology Part of CK Life Sciences International (Holdings), Inc., Polynoma LLC is an immuno-oncology focused biopharmaceutical company headquartered in San Diego, CA. Polynoma's lead asset is a novel polyvalent antigen vaccine, Seviprotimut-L, for the prevention of recurrence of melanoma. The vaccine has been safely administered in more than 1,000 patients. Polynoma is an immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. The private company was founded by Paul A. Hopper.
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA.
Sonus Pharmaceuticals, Inc.
Sonus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sonus Pharmaceuticals, Inc. engaged in the development of drugs for the treatment of cancer and related therapies. Its primary product TOCOSOL Paclitaxel, was an injectable paclitaxel emulsion for nonsmall cell lung cancer, ovarian cancer and bladder cancer. Sonus Pharmaceuticals was incorporated in 1991 and was headquartered in Bothell, WA.
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | 10 years |
Steven Gillis | M | 71 |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | 12 years |
Eric Dobmeier | M | 55 | 7 years | |
R. Adams | M | 57 | 3 years | |
Timothy Johnson | M | 62 | 13 years | |
Peter Thompson | M | 64 |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | 10 years |
Christopher Schelling | M | 48 | 6 years | |
Cameron Lawrence | M | 44 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | 4 years |
Chad Cohen | M | 49 | 7 years | |
Jack Goldstein | M | 77 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | 7 years |
Harry Palmin | M | 54 | 6 years | |
Harry Allan George | M | 76 | 20 years | |
John Bencich | M | 47 |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | 3 years |
Gregory R. Cox | M | 58 | 10 years | |
Mark McDade | M | 69 |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | 6 years |
Shing-Yin Tsui | F | 53 | 2 years | |
Jerry Wan | M | 42 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | 6 years |
James T. LaFrance | M | 65 | 7 years | |
Jason Amello | M | 55 | 6 years | |
Neil James Clendeninn | M | 74 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | - |
Andrew King | M | 44 | 4 years | |
Andris A. Zoltners | M | 78 | 11 years | |
Nancy Hill | F | 60 | 8 years | |
David Goel | M | 54 | 5 years | |
Erin S. Cox | F | - | 1 years | |
Dolca Thomas | M | 53 | 3 years | |
Jerel Davis | M | 47 | 5 years | |
Michael Houston | M | 61 | 3 years | |
Rachael Chesser | F | - | 9 years | |
Robert Azelby | M | 56 | - | |
Mahesh Krishnan | M | 53 | - | |
Stephen Charles Anderson | M | 61 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | 2 years |
Jaime Welch | F | - |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | - |
Hubert Birner | M | 57 | 2 years | |
Srini Akkaraju Akkaraju | M | 56 | 4 years | |
Stephen Aselage | M | 73 | 6 years | |
Martin Mattingly | M | 66 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | 7 years |
David Smith | M | 64 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | - |
Leslie Trigg | F | 53 | - | |
Kevin Conroy | M | 58 | 4 years | |
Obi Greenman | M | 57 | 13 years | |
Peggy Phillips | F | 70 | 2 years | |
H. Parker | F | 68 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | - |
Steven Reed | M | 73 |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | 10 years |
Cynthia Shumate | F | 62 |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | 7 years |
John Dunn | M | 72 | 6 years | |
Donnie Hardison | M | 74 | 7 years | |
Richard Ulevitch | M | 80 | 2 years | |
Luc Marengère | M | 59 | 2 years | |
Thomas DeZAo | M | 66 |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | 3 years |
Cindy Jacobs | M | 66 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA.
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | 6 years |
Ross Haghighat | M | 60 | 14 years | |
Maureen Howard | M | 70 |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | 4 years |
Robert Copeland | M | - |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | 5 years |
Wayne Gombotz | M | 64 |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | 3 years |
Russell Hawkinson | M | 65 |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | 10 years |
Byron Lawson | M | 49 | 11 years | |
Jay Robinson | M | - | - | |
Stanford J. Stewart | M | 71 |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | 4 years |
Carter J. King | M | 52 |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | 4 years |
Samuel Saks | M | 69 |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | 4 years |
Don Soland | M | 65 |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | 9 years |
John C. Cheneval | M | - | 3 years | |
Martin A. Cheever | M | - |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | - |
Sam M. Rua | M | - | 10 years | |
Lori Stewart | F | - | 5 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michelle Griffin
- Personal Network